In recent days, Spire has attracted a series of analyst upgrades and improved outlooks amid favorable regulatory changes in Missouri and its planned acquisition activity in Tennessee. Analysts cite ...
Alnylam Pharmaceuticals reported third-quarter 2025 earnings, achieving US$1.25 billion in revenue and a net income of US$251.08 million, while also raising full-year revenue guidance to between US$2.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback